Rare allele enrichment technology by PCR that enables the selective amplification and detection of low-abundant sequence variants down to 0.01% variant allele frequency (VAF).
NGS-based method that utilizes unique molecular identifiers (UMIs) and highly multiplexed partially nested PCR primer design to detect mutations and copy number variations with high sensitivity.Houston, TX, Jun 02, 2022 — NuProbe Global, a genomics and molecular diagnostics company, announces the close of its $50M…
Read More
Products & Services
VarMap® Pan-Cancer NGS Panel
The only liquid biopsy panel to detect 0.1% VAF requiring only 1 million NGS reads
Overview
The VarMap Pan-Cancer NGS Panel enables highly sensitive variant detection and quantitation across hundreds of loci in 61 genes. Utilizing BDA technology and next-generation sequencing, the VarMap Pan-Cancer panel significantly improves the limit of detection (≥0.1% VAF) while reducing the number of reads required. The panel is compatible with several sample types, including cell-free DNA, tumor sections, and PBMC DNA.
Key Features
- Detect SNVs and indels down to 0.1% VAF
- Requires only 1 million NGS reads per sample
- Compatible with tumor-derived or cell-free DNA
- Simple and user-friendly workflow and bioinformatics
CNV+ Breast Cancer NGS Panel
Accurately detect SNVs and indels in 14 genes and CNVs across 18 genes associated with breast cancer
Overview
The CNV+ Breast Cancer NGS Panel covers 84 frequently mutated breast cancer hotspots in 14 genes and CNVs of 18 genes including HER2. Using QASeq technology, the CNV+ Breast Cancer NGS Panel accurately quantifies SNVs and indels down to 0.2% VAF and detects CNVs in HER2 at 2.04/1.97 single heterozygous copy gain/loss from cfDNA or tumor tissue.
Key Features
- Detect SNVs and indels at 0.2% VAF
- Detect CNVs at 2.04/1.94 ploidy
- Compatible with tumor-derived or cell-free DNA
VarTrace® MSI Assay
Highly sensitive detection of microsatellite instability in five MSI loci using qPCR.
Overview
NuProbe’s VarTrace MSI Assay enables detection of MSI-high (MSI-H) status with a limit of detection down to 1% in five mononucleotide markers (BAT-25, BAT-26, NR-21, NR-24, and MONO-27).
Key Features
- Matched normal not required
- Results in less than two hours
- Compatible with tumor tissue or cell-free DNA
- Limit of detection down to 1% VAF
VarTrace® qPCR/Sanger Assays
qPCR/Sanger assays to identify variants down to 0.1% VAF
Key Features
- Detect targeted variants down to 0.1% VAF
- Same-day results
- Compatible with a variety of instruments
Augury™ Biopharma Services
Custom solutions for your biomarker needs
Overview
The Augury Biopharma Services leverage our proprietary technologies to create optimal solutions for your process, across test modalities such as next-generation sequencing (NGS) and qPCR. The flexibility of our platform facilitates the design of custom solutions across numerous diseases and applications.
Key Features
- Solutions for every step, from Research Use Only to clinical trial
- Assay development and validation, kit manufacturing, and sample testing services
- Proprietary PCR and NGS technologies compatible with liquid biopsy and tissue samples
- Best-in-class sensitivity to detect a wide range of alterations
Accelerating Precision Oncology Worldwide
Clinical and Research Laboratories
At NuProbe, we are developing innovative assays to accelerate cancer research. Our products allow laboratories to detect and quantify low-abundant variants across multiple platforms from both cell-free DNA and tissue specimens. Contact us today to learn more.
Pharma
We provide assay development and testing services to support all stages of biomarker detection programs. Our flexible platform utilizes proprietary technologies to deliver best-in-class sensitivity from solid tumor and liquid biopsy. Contact one of our experts today to find out what NuProbe can do for you.
Never miss an update
Stay in touch for the latest NuProbe developments
News & Press Releases
SADDLE approach uses computational primer design to minimize primer-dimer formation, and thus does not require enzymatic primers and primer-dimer removal.
The results show detection of CNVs down to 5% heterozygous single copy gain or loss, and mutations down to 0.1% variant allele frequency (VAF), from both formalin-fixed, paraffin-embedded (FFPE) tissue samples and from cell-free DNA (cfDNA) samples1.
Upcoming Events
September 21-22, 2022
World CB & CDx
